{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:29:07Z","timestamp":1773152947415,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.schres.2012.11.010","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T19:12:23Z","timestamp":1354648343000},"page":"60-64","source":"Crossref","is-referenced-by-count":10,"title":["Attaining and sustaining remission of predominant negative symptoms"],"prefix":"10.1016","volume":"143","author":[{"given":"Stephen Z.","family":"Levine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.schres.2012.11.010_bb0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.schres.2008.09.014","article-title":"Symptom remission in first episode patients","volume":"106","author":"Addington","year":"2008","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2012.11.010_bb0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/schbul\/sbj056","article-title":"An industry perspective on the NIMH consensus statement on negative symptoms","volume":"32","author":"Alphs","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2012.11.010_bb0015","series-title":"Scale for the Assessment of Negative Symptoms","author":"Andreasen","year":"1983"},{"key":"10.1016\/j.schres.2012.11.010_bb0020","series-title":"Scale for the Assessment of Positive Symptoms","author":"Andreasen","year":"1983"},{"issue":"3","key":"10.1016\/j.schres.2012.11.010_bb0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2012.11.010_bb0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/schbul\/16.2.293","article-title":"Gender and the course of schizophrenia: differences in treated outcomes","volume":"16","author":"Angermeyer","year":"1990","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.schres.2012.11.010_bb0035","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.pnpbp.2008.06.008","article-title":"Comparative remission rates of schizophrenic patients using various remission criteria","volume":"32","author":"Beitinger","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2012.11.010_bb0040","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1176\/appi.ajp.163.3.418","article-title":"Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms","volume":"163","author":"Bowie","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2012.11.010_bb0045","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1176\/ajp.156.4.610","article-title":"Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group","volume":"156","author":"Danion","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2012.11.010_bb0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.schres.2006.09.013","article-title":"Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates","volume":"89","author":"Emsley","year":"2007","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2012.11.010_bb0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.schres.2010.08.039","article-title":"Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS)","volume":"124","author":"Forbes","year":"2010","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.schres.2012.11.010_bb0060","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sj.mp.4002062","article-title":"The pipeline and future of drug development in schizophrenia","volume":"12","author":"Gray","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2012.11.010_bb0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1034\/j.1600-0447.2000.00008.x","article-title":"Onset and early course as determinants of the further course of schizophrenia","volume":"407","author":"Hafner","year":"2000","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"2","key":"10.1016\/j.schres.2012.11.010_bb0070","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/schbul\/sbj011","article-title":"Negative symptoms and cognitive deficits: what is the nature of their relationship?","volume":"32","author":"Harvey","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.schres.2012.11.010_bb0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.schres.2011.06.030","article-title":"Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS)","volume":"132","author":"Horan","year":"2011","journal-title":"Schizophr. Res."},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2012.11.010_bb0080","first-page":"25","article-title":"An evidence-based strategy for remission in schizophrenia","volume":"69","author":"Kane","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2012.11.010_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2012.11.010_bb0095","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/schbul\/sbj054","article-title":"Subdomains within the negative symptoms of schizophrenia: commentary","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2012.11.010_bb0090","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2012.11.010_bb0100","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbq059","article-title":"The brief negative symptom scale: psychometric properties","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2012.11.010_bb0125","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1176\/appi.ajp.159.2.180","article-title":"Amisulpride, an unusual \u201catypical\u201d antipsychotic: a meta-analysis of randomized controlled trials","volume":"159","author":"Leucht","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2012.11.010_bb0105","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-007-0857-1","article-title":"On the concept of remission in schizophrenia","volume":"194","author":"Leucht","year":"2007","journal-title":"Psychopharmacology (Berl.)"},{"issue":"1\u20133","key":"10.1016\/j.schres.2012.11.010_bb0130","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.schres.2008.01.018","article-title":"Predicting antipsychotic drug response \u2014 replication and extension to six weeks in an international olanzapine study","volume":"101","author":"Leucht","year":"2008","journal-title":"Schizophr. Res."},{"issue":"9657","key":"10.1016\/j.schres.2012.11.010_bb0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2012.11.010_bb0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","article-title":"Definitions of response and remission in schizophrenia: recommendations for their use and their presentation","volume":"438","author":"Leucht","year":"2009","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"9671","key":"10.1016\/j.schres.2012.11.010_bb0120","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0140-6736(09)60723-6","article-title":"Are new drugs for schizophrenia better than old ones? Authors' reply","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2012.11.010_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.0065-1591.2000.0ap25.x","article-title":"Sex differences in schizophrenia, a review of the literature","volume":"401","author":"Leung","year":"2000","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2012.11.010_bb0140","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.euroneuro.2012.03.001","article-title":"Delayed- and Early- Onset Hypotheses of Antipsychotic Drug Action in the Negative Symptoms of Schizophrenia","volume":"22","author":"Levine","year":"2012","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2012.11.010_bb0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.schres.2011.09.018","article-title":"Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study","volume":"133","author":"Levine","year":"2011","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.schres.2012.11.010_bb0150","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0006-3223(01)01303-8","article-title":"The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches","volume":"50","author":"Lieberman","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2012.11.010_bb0155","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2012.11.010_bb0160","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/bjp.170.1.18","article-title":"Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia","volume":"170","author":"Loo","year":"1997","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2012.11.010_bb0165","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/schbul\/sbq161","article-title":"Methodological issues in negative symptom trials","volume":"37","author":"Marder","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2012.11.010_bb0170","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2012.11.010_bb0180","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.schres.2006.07.007","article-title":"A population based elaboration of the role of age of onset on the course of schizophrenia","volume":"88","author":"Rabinowitz","year":"2006","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2012.11.010_bb0175","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2012.01.015","article-title":"Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data","volume":"137","author":"Rabinowitz","year":"2012","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2012.11.010_bb0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oxfordjournals.schbul.a006931","article-title":"Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?","volume":"28","author":"Storosum","year":"2002","journal-title":"Schizophr. Bull."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099641200624X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099641200624X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T12:27:20Z","timestamp":1687868840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092099641200624X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S092099641200624X"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2012.11.010","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}